Compare Abeona Therapeutics Inc (ABEO) vs Danaos Corporation (DAC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Danaos Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Danaos Corporation trades at $126.29 (market cap $2.27B). The key difference: Danaos Corporation is far larger — about 6.1× Abeona Therapeutics Inc's market cap, and Danaos Corporation pays a 2.88% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | DAC | |
|---|---|---|
Market Cap | $373.32M | $2.27B |
Sector | Health | Technology |
52-Week High | $7.23 | $134.63 |
52-Week Low | $4.17 | $84.05 |
Enterprise Value | $228.22M | $2.28B |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Danaos Corporation (DAC) trades at $125.34, up 2.47% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 4.42 and net income margin near 50%, supported by consistent dividend payments. Recent earnings beat expectations in two of the last three quarters, with Q2 2026 results pending.
Outlook remains positive due to deep value metrics and robust cash flow, but risks include cyclical shipping demand and capital expenditure pressures. Analyst sentiment is mixed with 40% buy ratings, suggesting cautious optimism amid solid operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Danaos Corporation
Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.
Read more on DAC →
